Athos Therapeutics develops AI-based precision therapeutics targeting Inflammatory Bowel Disease and other autoimmune conditions by integrating medicinal chemistry with machine learning to identify novel drug compounds. Their platform utilizes human clinical and molecular datasets to synthesize small molecules that effectively target key disease factors, improving treatment outcomes for patients.
Funding
$59.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for Inflammatory Bowel Disease (IBD) and other autoimmune conditions often lack precision, leading to suboptimal outcomes and potential side effects for patients. Identifying effective drug compounds that target key disease factors remains a significant challenge in autoimmune disease therapeutics.
Solution
Athos Therapeutics is developing AI-driven precision therapeutics for autoimmune diseases, including IBD. The company's platform integrates medicinal chemistry and systems biology with machine learning to discover novel drug candidates. Athos leverages human clinical and molecular datasets to identify disease-relevant factors. Their approach involves synthesizing small molecules using a computational medicinal chemistry platform and machine learning algorithms to pinpoint compounds that can safely and efficiently target key disease factors. This integrated approach aims to improve treatment outcomes for patients with autoimmune and chronic inflammatory diseases.
Target Audience
The primary target audience includes patients suffering from Inflammatory Bowel Disease and other autoimmune conditions, as well as pharmaceutical companies seeking innovative drug candidates for these diseases.
Features
- AI-driven drug discovery platform for autoimmune and inflammatory diseases
- Integration of medicinal chemistry, systems biology, and machine learning
- Utilization of human clinical and molecular datasets to identify novel drug targets
- Computational medicinal chemistry platform for synthesizing small molecules
- Machine learning algorithms to identify compounds that effectively target key disease factors